HIV Remission in a Woman of Mixed Race with AML and HIV: The New York Patient

Marshall Glesby, MD, PhD
Associate Chief, Division of Infectious Diseases
Director, Cornell HIV Clinical Trials Unit
Weill Cornell Medical College, New York, NY

- and -

Deborah Persaud, MD, PhD
Professor, Department of Pediatrics
Interim Chief, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Dept. of Molecular Microbiology and Immunology and International Health
Johns Hopkins Bloomberg School of Public Health
Chair, IMPAACT HIV Cure Scientific Committee, Baltimore, MD



How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenters:Top of page

Marshall J. Glesby, MD, PhD, is a Professor of Medicine and Population Health Sciences, Director of the HIV Clinical Trials Unit, and Associate Chief of the Division of Infectious Diseases in the Department of Medicine at Weill Cornell Medical College. His research focuses on metabolic complications and co-morbidities in people living with HIV infection. Dr. Glesby is a graduate of the Johns Hopkins University School of Medicine and has a Ph.D. in Clinical Investigation from the Johns Hopkins School of Hygiene and Public Health. Deborah Persaud, MD, PhD, is a clinician and researcher specializing in the study and treatment of HIV-1 infection in children and adolescents. A 1985 graduate of the New York University School of Medicine, she trained in pediatrics at Babies Hospital/Columbia Presbyterian Medical Center in New York, where she was chief resident. She was an infectious disease fellow, an Aaron Diamond Post-Doctoral Research Fellow and a faculty member at New York University. She joined Johns Hopkins’ faculty in 1997 following a visiting lectureship at the Moi University, Eldoret, Kenya.

Learning Objectives: Top of page

At the completion of this educational session, participants will:
1. Be able to Describe the barriers to HIV cure
2. Recognize why HIV remission and cure occurred through stem cell transplantation
3. Understand the relevance of different assays used to measure HIV persistence and its limitations in HIV cure research

CME Information:Top of page


This CME activity has approved for AMA PRA Category 1 Credit™ for May 18, 2022, as a live activity.  This activity will also be available as an enduring activity from May 19, 2022, through May 17, 2025.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun (Course Director) has no relevant financial relationships to disclose.

- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.

- Dr. Marshall Glesby (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Research Support from Gilead, and Regeneron; Consultant/DSMB Member to Swedish Orphan Biovitrum (Sobi), and Enzychem; Consultant to Regeneration, and ReAlta. Dr. Glesby will support their presentation and clinical recommendations with the best available evidence from the medical literature, and will submit their slides in advance for adequate peer review.

- Dr. Deborah Persaud (Presenter) has no relevant financial relationships to disclose. Dr. Persaud will support their presentation and clinical recommendations with the best available evidence from the medical literature, and will submit their slides in advance for adequate peer review.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

For more on the Berlin Patient please visit the link belowTop of page

The Berlin Patient: Eradication of HIV with CCR5 Deficient Hematopoietic Stem Cells

You must be logged in to post a comment. Login | Register